Beijing Biostar, a company based in the Beijing Economic-Technological Development Area (Beijing E-Town), was listed on the main board of the Stock Exchange of Hong Kong (HKEX) on Oct 31, becoming the first stock of "Synthetic Biology Medicine" in HKEX.

Focusing on the development of innovative oncology drugs driven by synthetic biology technology, Biostar relies on its advanced synthetic biology drug development platform to develop anti-cancer drugs with independent intellectual property rights. Its core product, Utidelone, is the world's first chemotherapeutic drug new molecule developed and marketed on the basis of synthetic biology technology. It is also the only microtubule inhibitor drug approved globally in over a decade with a novel molecular structure, and the first independently developed Class 1 innovative chemotherapy drug in China in nearly twenty years, breaking the treatment bottleneck in the field of advanced breast cancer in China.

At the same time, Biostar has successfully developed three core technology platforms focusing on the research and development of microbial metabolite-based new drugs. These platforms include the combinatorial biosynthesis platform, microbial fermentation production technology platform, and microbial drug formulation development platform. These platforms enable Biostar to continuously and efficiently obtain a foundation for "first-in-class" and "best-in-class" innovative anti-cancer drugs with high drug-like properties and strong expandability.

In addition to the Utidelone injection, Biostar has an additional 19 drug pipelines, including new products such as Utidelone capsules, Utidelone nanomedicines, Utidelone antibody-drug conjugates, BG22, and BG18.

"The successful listing this time is an important milestone in the development of Biostar and also a fresh start. In the future, we will continue to adhere to research and development and innovation, launch more innovative drug products, and at the same time bring our existing products to more patients, making a greater contribution to the cause of life and health," said Dr. Tang Li, chairman, executive director, chief scientific officer, and chief marketing officer of Biostar.

As of now, Beijing E-Town has 54 listed companies, both domestic and international, while also having a reserve of a group of companies preparing for listing. It implements hierarchical dynamic management, centralized and unified cultivation, and specialized key services. Going forward, Beijing E-Town will further enhance its efforts in nurturing listed companies, continuously optimizing its services to support companies to go public.